US: CKDXF - Opthea Ltd

Altı ay boyunca karlılık: -22.81%
Temettü getirisi: 0.00%

Promosyon programı Opthea Ltd

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Opthea Ltd

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

daha fazla ayrıntı
The company's lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema. It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://opthea.com
Цена ао 0.44
Günlük fiyat değişimi: 0% (0.44)
Haftalık fiyat değişimi: 0% (0.44)
Aylık fiyat değişimi: 0% (0.44)
3 ayda fiyat değişimi: 0% (0.44)
Altı ayda fiyat değişimi: -22.81% (0.57)
Yıllık fiyat değişimi: +51.72% (0.29)
3 yılda fiyat değişimi: -59.63% (1.09)
5 yılda fiyat değişimi: -81.89% (2.43)
Yılbaşından bu yana fiyat değişimi: 0% (0.44)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 1484.6 1
P/BV -2.44 0
P/E 0 0
EV/EBITDA -0.774 0
Toplam: 2.75

Yeterlik

İsim Anlam Seviye
ROA, % -130.72 0
ROE, % 520.65 10
Toplam: 3.33

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0.59

Görev

İsim Anlam Seviye
Debt/EBITDA -0.7108 10
Toplam: 9.8

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 107.95 10
karlılık Ebitda, % 1044.01 10
karlılık EPS, % 738.93 10
Toplam: 10
Daha fazla ayrıntı

Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Frederic Guerard M.S., Pharm.D. Chief Executive Officer 1972 (53 yıl)
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. Founder, Chief Innovation Officer & Executive Director 1975 (50 yıllar)
Ms. Karen Adams CPA VP of Finance & Company Secretary 1971 (54 yıl)
Mr. Daniel E. Geffken M.B.A. Interim CFO 1957 (68 yıllar)
Mr. Kevin Bitter VP of Strategy & Corporate Development 1992 (33 yıl)
Ms. Sarika Gulhar Ph.D. Executive Director of Human Resources
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Development 1965 (60 yıllar)
Dr. Kenneth Sall Chief Medical Officer
Dr. Fang Li Ph.D. Senior Vice President of Regulatory Affairs 1964 (61 yıl)
Dr. Julie Clark M.D., M.S. Senior Vice President of Clinical Development 1975 (50 yıllar)

Adres: Australia, South Yarra, 650 Chapel Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://opthea.com